UPMC Health Plan & Boehringer Ingelheim Announce Innovative, Value-Based Agreement

UPMC Health Plan recently announced it is forming a value-based agreement with Boehringer Ingelheim for Jardiance, effective beginning January 1, 2019. Jardiance (Empagliflozin) is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

The contract seeks to align Boehringer’s incentives with UPMC Health Plan, reimbursing Jardiance as it yields positive clinical outcomes for the real-world population. This agreement shifts the focus in health care to results, according to statements from UPMC. UPMC also states it selected Jardiance for the contract due to its ability to reduce cardiovascular . . .